Azitra Shares Soar 3.86% on $20M Share Purchase Deal

Azitra (AZTR) shares surged 3.86% today, marking the third consecutive day of gains, with a cumulative increase of 11.90% over the past three days. The stock price reached its highest level since February 2025, with an intraday gain of 29.03%.

The recent surge in Azitra's stock price can be attributed to a significant share purchase agreement with Alumni Capital LP. This $20 million deal provides Azitra with flexible funding over a 20-month period, allowing the company to gradually sell stock and warrants. This strategic financial move is designed to support Azitra’s clinical pipeline, including the ATR-12 program for Netherton Syndrome and the ATR-04 program for EGFR inhibitor-associated rash. The partnership with Alumni Capital, which focuses on small-cap equities in healthcare, signals confidence in Azitra’s innovative biotherapeutic approach, potentially driving investor interest and impacting stock valuation.